分红方面，可孚医疗A股上市后累计派现12.35亿元。近三年，累计派现9.78亿元。 机构持仓方面，截止2025年6月30日，可孚医疗十大流通股东中，国泰医药健康股票A（009805）位居 第九大流通股东，持股230.12万股，相比上期增加23.66万股。香港中央结算有限公司退出十大流通股东 之列。 责任编辑：小浪快报 融资方面，可孚医疗当日融资买入777.80万元。当前融资余额1.14亿元，占流通市值的1.42%，融资余 额超过近一年70%分位水平，处于较高位。 融券方面，可孚医疗10月9日融券偿还3900.00股，融券卖出1200.00股，按当日收盘价计算，卖出金额 4.62万元；融券余量2.10万股，融券余额80.64万元，超过近一年80%分位水平，处于高位。 资料显示，可孚医疗科技股份有限公司位于湖南省长沙市雨花区振华路816号,香港新界葵涌工业街23- 31号美联工业大厦22楼B单元，成立日期2009年11月19日，上市日期2021年10月25日，公司主营业务涉 及从事家用医疗器械的研发、生产、销售和服务。主营业务收入构成为：康复辅具类产品43.12%，医 疗护理类产品32.45%，健康监测类产品20 ...

融券方面，可孚医疗9月25日融券偿还300.00股，融券卖出6500.00股，按当日收盘价计算，卖出金额 25.16万元；融券余量2.23万股，融券余额86.11万元，超过近一年90%分位水平，处于高位。 资料显示，可孚医疗科技股份有限公司位于湖南省长沙市雨花区振华路816号,香港新界葵涌工业街23- 31号美联工业大厦22楼B单元，成立日期2009年11月19日，上市日期2021年10月25日，公司主营业务涉 及从事家用医疗器械的研发、生产、销售和服务。主营业务收入构成为：康复辅具类产品43.12%，医 疗护理类产品32.45%，健康监测类产品20.76%，其他(补充)3.68%。 9月25日，可孚医疗跌1.43%，成交额8122.81万元。两融数据显示，当日可孚医疗获融资买入额611.88 万元，融资偿还968.20万元，融资净买入-356.32万元。截至9月25日，可孚医疗融资融券余额合计1.26 亿元。 融资方面，可孚医疗当日融资买入611.88万元。当前融资余额1.25亿元，占流通市值的1.55%，融资余 额超过近一年80%分位水平，处于高位。 截至8月29日，可孚医疗股东户数1.90万，较上期增加 ...

Core Viewpoint - Kefu Medical has submitted a listing application to the Hong Kong Stock Exchange, aiming to raise funds for expanding overseas sales channels, global investments and acquisitions, research and development innovations, and domestic market promotion [1] Group 1: Company Overview - Kefu Medical is a leading enterprise in China's home medical device industry, with over 200 product categories [1] - The company ranks second in sales in China for 2024 [1] - Kefu Medical is actively expanding its online channels, covering all major e-commerce platforms, and is projected to rank second in online sales in the industry for 2024 [1] Group 2: Business Operations - As of June 30, 2025, Kefu Medical operates 738 self-owned stores, with 689 being "Jianer Hearing" service centers, covering 135 cities nationwide [1] - The rehabilitation aids segment is the most significant growth area for revenue, particularly in correction, posture correction products, and hearing aids [1]

Group 1 - The core viewpoint of the news is that Kefu Medical has experienced a decline in stock price and trading volume, with significant net financing outflows on September 15 [1] - As of September 15, Kefu Medical's financing balance is 1.50 billion yuan, with a net financing outflow of 815.54 million yuan for the day [1] - The company has a high financing balance, accounting for 1.80% of its market capitalization, which is above the 90th percentile level over the past year [1] Group 2 - Kefu Medical's revenue for the first half of 2025 is reported at 1.496 billion yuan, a year-on-year decrease of 4.03%, while the net profit attributable to shareholders is 167 million yuan, down 9.51% year-on-year [2] - The company has distributed a total of 1.235 billion yuan in dividends since its A-share listing, with 978 million yuan distributed in the last three years [3] - As of June 30, 2025, Kefu Medical's top ten circulating shareholders include Guotai Medical Health Stock A, which increased its holdings by 236,600 shares [3]

Core Viewpoint - Company Kefu Medical has submitted an application for listing on the Hong Kong Stock Exchange, aiming for a dual listing after its previous listing on the Shenzhen Stock Exchange in 2021 [3][4]. Company Overview - Kefu Medical is one of the largest home medical device companies in China, established in 2007, focusing on providing convenient solutions for consumers and patients seeking high-quality home medical devices [3][5]. - The company has significant competitive advantages in various verticals of the home medical device industry, ranking second among all home medical device companies in China based on projected domestic revenue for 2024 [3][5]. Financial Performance - For the six months ending June 30, 2025, Kefu Medical reported revenue of approximately 1.496 billion RMB, a year-on-year decrease of about 4.0%, and a net profit attributable to shareholders of approximately 167 million RMB, down 9.5% year-on-year [3][4][14]. Fundraising Purpose - The net proceeds from the IPO are intended for global expansion, ongoing product research and technological innovation, including applications of artificial intelligence and the Internet of Things, expanding domestic sales channels and distribution networks, brand promotion, and general corporate purposes [4][5]. Product Strategy - Kefu Medical strategically focuses on five categories of home medical devices with strong growth potential: rehabilitation aids, medical care products, traditional Chinese medicine therapy products, health monitoring products, and respiratory support products [6][16]. - The company offers a comprehensive product range with over 200 products and thousands of specifications, enhancing its position as a one-stop solution for consumers' medical needs [6][16]. Sales Network - Kefu Medical has developed a broad and deep sales network in China, with significant overseas influence, covering both online and offline channels [7][9]. - The online sales revenue reached 1.9807 billion RMB in 2024, with full coverage of major e-commerce platforms such as Tmall, JD.com, Douyin, Xiaohongshu, Pinduoduo, and Yaoshi Bang [10][11]. Market Position - According to Frost & Sullivan, Kefu Medical ranks first in the online revenue segment of the home medical device market in China for 2024 [11][12]. - The company has expanded its global footprint, reaching over 60 countries and regions across Asia, Africa, Europe, and the Americas [13].

Core Viewpoint - Kefu Medical Technology Co., Ltd. is seeking to list on the Hong Kong Stock Exchange, aiming to enhance its global strategy and brand recognition after its previous listing on the ChiNext in 2021 [1][7] Group 1: Financial Performance - Kefu Medical's revenue for 2022, 2023, 2024, and the first half of 2025 was RMB 29.77 billion, RMB 28.54 billion, RMB 29.83 billion, and RMB 14.96 billion respectively [2] - Gross profit for the same periods was RMB 11.27 billion, RMB 11.73 billion, RMB 15.09 billion, and RMB 7.48 billion, with corresponding gross margins of approximately 37.84%, 41.09%, 50.58%, and 49.99% [2] - Net profit figures were RMB 3.02 billion, RMB 2.53 billion, RMB 3.12 billion, and RMB 1.67 billion, with net profit margins of about 10.15%, 8.86%, 10.47%, and 11.14% [2] Group 2: Product and Market Position - Kefu Medical's core business is product sales, contributing approximately 90% of total revenue, with sales figures of RMB 27.99 billion, RMB 26.42 billion, RMB 27.37 billion, and RMB 13.07 billion for the years 2022 to 2025 [2] - The revenue from rehabilitation aids increased significantly from RMB 5.26 billion in 2022 to RMB 10.4 billion in 2024, reaching RMB 5.31 billion in the first half of 2025, accounting for over 35% of total revenue [3] - Kefu Medical ranks first in the market for home rehabilitation aids and posture correction products, with a market share of nearly 30% [4] Group 3: Market Trends and Growth Potential - The global medical device market is projected to reach USD 869.7 billion by 2030, driven by factors such as aging population and increased healthcare spending [6] - The Chinese home medical device market is expected to grow from RMB 1,224 billion in 2019 to RMB 3,131 billion by 2030, with a compound annual growth rate of 7.9% [7] - Kefu Medical's overseas revenue was approximately RMB 59.15 million in 2024, representing only 1.98% of total revenue, but showed significant growth with a 200% increase in the first half of 2025 [7]

Core Viewpoint - Kefu Medical Technology Co., Ltd. has submitted an application for a dual listing on the Hong Kong Stock Exchange, marking the official start of its A+H dual listing strategy, following its previous listing on the A-share market [1][5]. Group 1: Company Overview - Kefu Medical, established in 2007, focuses on five categories of home medical devices, including rehabilitation aids, medical care products, health monitoring devices, respiratory support products, and traditional Chinese medicine therapy products, making it one of the largest home medical device companies in China [5][6]. - According to Frost & Sullivan, Kefu Medical ranks second among all home medical device companies in China by sales revenue for 2024 [6]. Group 2: Financial Performance - Kefu Medical's revenue for the years 2022 to 2025 (first half) is approximately 2.977 billion, 2.854 billion, 2.983 billion, and 1.496 billion yuan, respectively, with a compound annual growth rate of 2.9% over the past three years [7]. - The company's net profit for the same period is approximately 302 million, 253 million, 312 million, and 167 million yuan, indicating a decline in profitability in 2023, with a further 9.5% year-on-year decrease in net profit in the first half of 2025 [8]. Group 3: Market Position and Strategy - Kefu Medical has achieved significant online sales success, with 2024 online sales reaching 1.981 billion yuan, ranking second among home medical device companies in China [10]. - The company has established a comprehensive presence on major e-commerce platforms, leveraging "Douyin + e-commerce" strategies to capture market share [11]. - Kefu Medical is actively expanding its overseas business, with international revenue accounting for only 1.98% of total revenue in 2024, but showing significant growth of over 200% in the first half of 2025 [11]. Group 4: Future Plans - The funds raised from the Hong Kong listing will primarily be used for product research and development, global sales network expansion, business development, brand marketing, and supplementing working capital [11].

Investment Rating - The investment rating for the company is "Buy" [17] Core Views - The company has shown a strong performance in its rehabilitation aids segment, with a significant revenue increase of 42.77% year-on-year [6] - The company is focusing on core product categories and enhancing R&D efficiency, leading to rapid innovation and product launches [7] - The hearing aid business is developing steadily, with a revenue growth of 37.86% year-on-year, indicating potential for becoming a second growth curve for the company [10] Company Overview - The latest closing price is 32.97 yuan, with a total market capitalization of 6.9 billion yuan [4] - The company reported a revenue of 2.983 billion yuan in 2024, a year-on-year increase of 4.53%, and a net profit of 312 million yuan, up 22.60% [5] - The company has a debt-to-asset ratio of 25.2% and a price-to-earnings ratio of 21.55 [4] Financial Performance - The company expects revenues of 3.449 billion yuan, 4.032 billion yuan, and 4.747 billion yuan for 2025, 2026, and 2027 respectively, with year-on-year growth rates of 15.6%, 16.9%, and 17.7% [11] - The projected net profit for 2025, 2026, and 2027 is 389 million yuan, 454 million yuan, and 564 million yuan, with growth rates of 24.9%, 16.7%, and 24.0% respectively [11] - The company has launched over a hundred new products in 2024, enhancing its product portfolio significantly [7]

Investment Rating - The report assigns a "Buy" rating for the stock, indicating an expected relative price increase of over 20% compared to the benchmark index within the next six months [17]. Core Insights - The company, Kefu Medical, reported a revenue of 2.983 billion yuan for 2024, a year-on-year increase of 4.53%, and a net profit attributable to shareholders of 312 million yuan, up 22.60% year-on-year [5]. - The company is focusing on home medical care, with significant growth in rehabilitation aids, which generated 1.104 billion yuan in revenue, a 42.77% increase [6]. - Kefu Medical launched over a hundred new products in 2024, enhancing its product portfolio in the high-end respiratory support field and other medical devices [7]. - The company has established a multi-channel marketing strategy, achieving 1.990 billion yuan in online sales, a growth of 8.94% [8]. - The hearing aid business is developing steadily, with a revenue of 273 million yuan in 2024, reflecting a growth of 37.86% [10]. - Revenue projections for 2025-2027 are 3.449 billion yuan, 4.032 billion yuan, and 4.747 billion yuan, with corresponding net profits of 389 million yuan, 454 million yuan, and 564 million yuan [11]. Financial Summary - As of the latest report, the company's total market capitalization is 6.9 billion yuan, with a price-to-earnings ratio of 21.55 [4]. - The company’s asset-liability ratio stands at 25.2%, indicating a solid financial position [4]. - The projected earnings per share (EPS) for 2025, 2026, and 2027 are 1.86 yuan, 2.17 yuan, and 2.70 yuan respectively [11].

相关研究 [Table_OtherReport] 销售毛利率逐季提升，长期成长可期 核心品类同比增 30%+, 盈利能力提升 可期 五大产品线均衡发展, 听力保健成长 可期 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 聚焦核心品类，结构调整提升盈利能力 证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 可孚医疗(301087) | 投资评级 | 买入 | | --- | --- | | 上次评级 | 买入 | | 执业编号：S1500523080002 | | | --- | --- | | [Table_Author] 唐爱金 邮 | 医药行业首席分析师 箱：tangaijin@cindasc.com | 曹佳琳 医药行业分析师 执业编号：S1500523080011 邮 箱：caojialin@cindasc.com [Table_ReportDate] 2025 年 05 月 05 日 [Table_S 事件：公 ...